After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going ...

1. Nature Biotechnology published the letter, which 165 biotech executives signed, that details the industry’s “deep concern and opposition to the executive order.” 2. The letter says of the nearly 69 ...

The third quarter was a pivotal period for both the biotech and pharmaceutical sectors, with regulatory developments and an increase in business deals shaping the landscape for the industries. Public ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...

New Taipei City, Taiwan, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (MENS) (the “Company” or “Jyong Biotech”) notes the recent fluctuation in its share price and the increased trading volume ...

Welcome to another edition of Core Biotech!I started this portfolio with the objective of proving that Long-Term investing in the biotech sector is a worthwhile endeavor.New buys and sells are ...